On May 12, 2025, Imunon, Inc. (IMNN) announced financial results for the first quarter of 2025 and provided a business update. The company recently announced that the first clinical trial site for the Phase 3 OVATION 3 trial of IMNN-001 in patients with advanced ovarian cancer is activated and a second site will be activated this week. Imunon previously reported results from the Phase 2 OVATION 2 trial that showed IMNN-001 plus neoadjuvant and adjuvant chemotherapy (NACT) increased median overall survival (OS) to 46 months vs. 33 months for standard-of-care NACT. In addition, IMNN-001 was well tolerated and had an excellent safety profile. New data from the OVATION 2 trial was accepted for oral presentation at the 2025 ASCO Meeting, further validating the importance of that data. While the company is still exploring its options, we anticipate news this quarter regarding how the OVATION 3 trial will be financed.
